INAB (INAB) Stock Price & Analysis
INAB (INAB) rose 3.45% to USD 1.2 as of September 8, 2026 at 06:23 UTC, according to Nexqual real-time market data.
INAB last closed at USD 1.2; the session ranged USD 1.16–1.22 on volume of 22,389 shares. Market capitalization is —, with a 52-week range of USD 0.88–2.73 (NCM). Source: Nexqual, September 8, 2026 at 06:23 UTC.
Key Statistics (as of September 8, 2026 at 06:23 UTC)
| Price | USD 1.2 |
|---|---|
| Change | ▲ 3.45% (up) |
| Previous Close | USD 1.2 |
| Open | USD 1.2 |
| Day Range | USD 1.16 – 1.22 |
| 52-Week Range | USD 0.88 – 2.73 |
| Volume | 22,389 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (INAB)
Nexqual's technical model rates INAB "NEUTRAL" based on 3 bullish and 2 bearish signals across 128 daily candles, as of September 8, 2026 at 06:23 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 53.88 (neutral) |
| vs SMA50 | Above (USD 1.2) |
| MACD | -0.01 (negative) |
From INAB's Latest SEC 10-K Filing (filed 2026-03-12)
Source: SEC EDGAR 10-K. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CDIO | Cardio Diagnostics Holdings Inc | USD 1.86 | ▲ 1.09% |
| PXMD | PaxMedica, Inc. | USD 0 | ▼ 28.57% |
| SPRC | SciSparc Ltd. | USD 5.29 | ▼ 9.57% |
| DRMA | Dermata Therapeutics, Inc. | USD 1.21 | ▼ 5.47% |
| KPRX | Kiora Pharmaceuticals, Inc. | USD 2.55 | ▼ 1.54% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 06:23 UTC. This page is informational and not investment advice.